TD139, a novel inhaled galectin-3 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF). Results from the first in human study in healthy volunteers

Authors
Category Primary study
JournalAmerican Journal of Respiratory and Critical Care Medicine
Year 2015
This article has no abstract
Epistemonikos ID: 2b2612038b0fee99b4b8cfb8e1d90312d5603a28
First added on: Feb 07, 2025